MVA-MAGEA3
- Generic Name
- MVA-MAGEA3
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Phase 1
Suspended
- Conditions
- Non-small Cell Lung Cancer (NSCLC)Esophageal NeoplasmsNeoplasms, Squamous Cell
- Interventions
- Combination Product: Standard of care treatmentBiological: ChAdOx1-MAGEA3-NYESOBiological: MVA-NYESO
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 15
- Registration Number
- NCT04908111
- Locations
- 🇬🇧
Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom
🇬🇧Blackpool Victoria Hospital, Blackpool, United Kingdom
🇬🇧The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath